We are expanding to Sweden

We are taking another important step in our pan-European growth strategy by entering the Swedish vaccination market. ELCG has acquired two vaccination clinics in Uppsala län, north of Stockholm.

With our strong presence in the United Kingdom and the Netherlands, we have already built a solid international foundation. Now we are expanding our activities to Sweden, which is a natural next step in our strategy to grow in Northern Europe.

Sweden is an attractive market. It is both large and fragmented, with many smaller players, which provides us with an opportunity to professionalize and grow the market. Our business model, which has already proven successful in Denmark, is directly transferable to the Swedish market. We therefore see this as a natural extension of our existing activities and an exciting new chapter in our journey.

The two clinics acquired, Resecentrum Vaccinationer, are located in Uppsala and Enköping. Along with the acquisition, ELGC will are also taking over the clinics’ role in public vaccination programs and as well as strengthening our offerings in travel vaccinations. We see significant growth potential in vaccinations targeted at businesses and their employees, as well as in vaccinations against the TBE virus, which is spreading in Sweden. We expect that TBE vaccinations will already constitute a significant part of our activities at the two clinics from the outset.

ELCG brings extensive experience, which we are confident will further raise the quality level in the Swedish market. Our expertise in process management and healthcare professionalism makes us a strong partner capable of delivering safe and effective vaccination solutions.

Since founding our company in 1998, we have worked consistently to promote vaccination across Europe. In 2024 alone, ELCG administered nearly 2.9 million vaccinations. In the United Kingdom, we collaborate closely with the National Health Service (NHS), and in the Netherlands, we have doubled both volume and revenue in just one year following the acquisition of PreventVaccins and Vaccinaties Op Reis.

With our entry into the Swedish market, ELCG continues to expand our reach and contribute to better health through vaccination. We look forward to bringing our experience and high standards to yet another Northern European market.